HIV Dosing and OI Prophylaxis Guideline[removed]

First Page		Document Content
Date: 2011-06-30 14:50:44 Darunavir Tenofovir/emtricitabine Efavirenz Atazanavir Tipranavir Lopinavir/ritonavir Antiretroviral drug Delavirdine Ritonavir Chemistry Organic chemistry Protease inhibitors		HIV Dosing and OI Prophylaxis Guideline[removed] Add to Reading List Source URL: www.cumc.columbia.edu Download Document from Source Website File Size: 121,91 KB Share Document on Facebook

	AIDS InfoNet www.aidsinfonet.org Fact Sheet Number 433 DELAVIRDINE (Rescriptor) DocID: RZid - View Document
	Kentucky Department for Medicaid Services ProDUR Severity Level I Drug-to-Drug (DD) Interactions The following chart lists severity level I drug-to-drug interactions and recommendations for point-of-sale (POS) editing s DocID: LAIU - View Document
	Kentucky Department for Medicaid Services Drug Management Review Advisory Board (DMRAB) Recommendations for Consideration The following chart provides a summary of the recommendations that were made by the Drug Managemen DocID: LAAq - View Document
	Kentucky Department for Medicaid Services ProDUR Severity Level I Drug-to-Drug (DD) Interactions The following chart lists severity level I drug-to-drug interactions and recommendations for point-of-sale (POS) editing s DocID: LAsA - View Document
	These highlights do not include all the information needed to use LEXIVA safely and effectively. See full prescribing information for LEXIVA.LEXIVA (fosamprenavir calcium) Tablets, for oral useLEXIVA (fosamprenavir calci DocID: Kber - View Document